Security Snapshot

ACADIA PHARMACEUTICALS INC - COMMON STOCK (ACAD) Institutional Ownership

CUSIP: 004225108

13F Institutional Holders and Ownership History from Q1 2014 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

252

Shares (Excl. Options)

122.32MFull value: 122,319,533 · shares · 30 Sep 2026

Price

$20.15

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
-3,198,278
Value change
-$82,246,598
Number of holders
252
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
173,883,841
SEC-reported price per share
$19.74
Insider filing price
$19.74
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • ACAD - ACADIA PHARMACEUTICALS INC - COMMON STOCK is tracked under CUSIP 004225108.
  • 252 institutions reported positions in Q3 2026.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 351 to 252 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $4.27BFull value: $4,267,169,090 · USD · 30 Jun 2026
    to
    $2.46BFull value: $2,464,523,208 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 252 institutions filings for Q3 2026.

Open SEC evidence

Security key

004225108

13F reference period

Q3 2026

13F holders

252

13D/G owners

5

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
5
Security
ACAD
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BAKER BROS. ADVISORS LP 25% $1,162,886,859 43,294,373 Julian C. Baker 24 Feb 2026
BlackRock, Inc. 12% $292,813,929 19,878,746 BlackRock, Inc. 31 Jan 2025
VANGUARD PORTFOLIO MANAGEMENT LLC 5.2% $195,465,216 8,781,007 Vanguard Portfolio Management 31 Mar 2026
STATE STREET CORP 4.4% -18% $154,165,413 -$28,720,258 7,650,889 -16% STATE STREET CORPORATION 30 Sep 2026
RTW INVESTMENTS, LP 4.2% -20% $152,464,142 -$33,311,249 7,144,524 -18% RTW Investments, LP 30 Sep 2025
As of 30 Sep 2026, 252 institutional investors reported holding
122.32MFull value: 122,319,533 · shares · 30 Sep 2026
shares of ACADIA PHARMACEUTICALS INC - COMMON STOCK (ACAD). This represents 70% of the company’s total
173.88MFull value: 173,883,841 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
61%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BAKER BROS. ADVISORS LP 25% 42,912,904 0% 4.1% $864,695,016
VANGUARD PORTFOLIO MANAGEMENT LLC 5.4% 9,457,124 +7% 0.01% $190,561,049
STATE STREET CORP 4.4% 7,650,889 -16% 0% $154,165,413
RTW INVESTMENTS, LP 4.1% 7,144,524 0% 1.5% $143,962,159
VANGUARD CAPITAL MANAGEMENT LLC 3.3% 5,790,801 +0.47% 0% $116,684,640
GOLDMAN SACHS GROUP INC 2.7% 4,621,932 +79% 0.01% $93,131,930
GEODE CAPITAL MANAGEMENT, LLC 1.9% 3,372,301 +0.42% 0% $67,965,261
DIMENSIONAL FUND ADVISORS LP 1.9% 3,366,052 -8.9% 0.01% $67,826,333
Palo Alto Investors LP 1.4% 2,485,608 -13% 7.5% $50,085,001
Qube Research & Technologies Ltd 1.4% 2,464,497 +0.73% 0.05% $49,659,615
TWO SIGMA INVESTMENTS, LP 1.3% 2,182,909 +135% 0.03% $43,985,616
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1.2% 2,129,573 +8.1% 0.02% $42,910,896
MORGAN STANLEY 0.85% 1,480,687 +56% 0% $29,835,864
Frazier Life Sciences Management, L.P. 0.83% 1,438,198 0% 0.72% $28,979,690
Point72 Asset Management, L.P. 0.65% 1,135,983 -53% 0.04% $22,890,057
RENAISSANCE TECHNOLOGIES LLC 0.64% 1,107,496 -14% 0.03% $22,316,044
BANK OF AMERICA CORP /DE/ 0.58% 1,008,636 -22% 0% $20,324,012
PANAGORA ASSET MANAGEMENT INC 0.54% 946,781 +33% 0.06% $19,077,637
VANGUARD FIDUCIARY TRUST CO 0.53% 921,614 +1% 0% $18,570,522
Invesco Ltd. 0.51% 888,800 +9.7% 0% $17,909,320
MILLENNIUM MANAGEMENT LLC 0.46% 795,315 +35% 0.01% $16,025,597
MARSHALL WACE, LLP 0.46% 794,317 -55% 0.02% $16,005,487
Artisan Partners Limited Partnership 0.42% 723,908 -45% 0.03% $14,586,746
Fisher Asset Management, LLC 0.41% 711,352 +1.7% 0% $14,333,756
RICE HALL JAMES & ASSOCIATES, LLC 0.35% 605,577 -2.2% 0.65% $12,202,377

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
51
Headline period
Q3 2026
Rows shown
1-25 of 51
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 122,319,533 $2,464,523,208 -$82,246,598 $20.15 252
2026 Q2 168,693,439 $4,267,169,090 +$103,673,036 $25.30 351
2026 Q1 164,826,344 $3,668,636,431 -$63,344,363 $22.26 344
2025 Q4 166,357,635 $4,442,297,638 -$75,199,637 $26.71 334
2025 Q3 167,660,004 $3,576,680,400 -$45,558,483 $21.34 329
2025 Q2 169,807,590 $3,663,065,967 -$28,402,837 $21.57 308
2025 Q1 171,490,817 $2,848,881,391 +$139,123,298 $16.61 315
2024 Q4 162,840,883 $2,987,247,881 +$134,856,202 $18.35 292
2024 Q3 155,896,219 $2,398,194,293 -$102,074,875 $15.38 257
2024 Q2 161,184,775 $2,619,212,148 -$8,478,472 $16.25 265
2024 Q1 161,305,797 $2,982,051,495 -$11,656,862 $18.49 266
2023 Q4 159,519,491 $4,994,576,405 +$146,161,056 $31.31 272
2023 Q3 156,109,164 $3,253,545,379 -$82,496,501 $20.84 246
2023 Q2 159,054,444 $3,809,481,545 +$45,597,747 $23.95 232
2023 Q1 158,037,917 $2,974,292,426 +$53,351,193 $18.82 231
2022 Q4 155,962,184 $2,482,889,933 +$28,684,244 $15.92 221
2022 Q3 152,629,101 $2,497,282,084 +$30,373,584 $16.36 213
2022 Q2 150,587,330 $2,121,823,126 +$730,128 $14.09 229
2022 Q1 147,043,761 $3,562,570,671 -$19,931,550 $24.22 254
2021 Q4 148,180,956 $3,457,975,885 +$79,727,176 $23.34 238
2021 Q3 144,785,492 $2,405,101,667 -$85,712,883 $16.61 221
2021 Q2 148,041,851 $3,610,234,111 +$54,424,511 $24.39 238
2021 Q1 145,061,195 $3,742,096,150 -$221,828,762 $25.80 258
2020 Q4 147,844,682 $7,903,754,877 -$103,617,443 $53.46 298
2020 Q3 150,041,187 $6,188,429,775 -$100,187,840 $41.25 262
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .